ArticleInternational journal of nanomedicine2018
Curdlan sulfate-
Article in International journal of nanomedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 57 citations in OpenAlex.
- Chitosan nanoparticles for mucosal and needle-free vaccination.NPJ vaccines · 2026Review
- Novel Quaternary Ammonium Derivatives Based on Apple Pectin.Polymers · 2024Article
- Advancements in Nanoparticle-Based Adjuvants for Enhanced Tuberculosis Vaccination: A Review.Vaccines · 2024Review
- Chitosan Nanoparticles for Intranasal Drug Delivery.Pharmaceutics · 2024Review
- New Quaternary Ammonium Derivatives Based on Citrus Pectin.Polymers · 2023Article
- Chitosan Hydrogel as Tissue Engineering Scaffolds for Vascular Regeneration Applications.Gels (Basel, Switzerland) · 2023Review
- The Role of Mucoadhesion and Mucopenetration in the Immune Response Induced by Polymer-Based Mucosal Adjuvants.Polymers · 2023Review
- Eco-friendly synthesis of chitosan and its medical application: from chitin extraction to nanoparticle preparation.ADMET & DMPK · 2023Review
- Review
- Preparation of Chitosan Nanoparticles as a Capable Carrier for Antigen Delivery and Antibody Production.Iranian journal of biotechnology · 2021Article
- Biomedical Applications of Quaternized Chitosan.Polymers · 2021Review
- Nanotechnology-based antiviral therapeutics.Drug delivery and translational research · 2021Review
- An Overview of Current Knowledge on the Properties, Synthesis and Applications of Quaternary Chitosan Derivatives.Polymers · 2020Review
- Review
- Advancements in prophylactic and therapeutic nanovaccines.Acta biomaterialia · 2020Review
- Nanoparticle-Based Vaccines Against Respiratory Viruses.Frontiers in immunology · 2019Review
- Lower-Sized Chitosan Nanocapsules for Transcutaneous Antigen Delivery.Nanomaterials (Basel, Switzerland) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe development of ideal vaccine adjuvants for intranasal vaccination can provide convenience for many vaccinations. As an ideal intranasal vaccine adjuvant, it should have the properties of assisting soluble antigens to pass the mucosal barrier and potentiating both systemic and mucosal immunity via nasal administration.
methodsBy using the advantages of polysaccharides, which can promote both T-helper 1 and 2 responses, curdlan sulfate (CS)-
resultsThe results showed that the polysaccharide-based nanoparticles induced the proliferation and activation of antigen-presenting cells. High protein-loading efficiency was obtained by testing with the model antigen ovalbumin (Ova), and the Ova adsorbed onto the cationic CS/
conclusionTherefore, these results suggest that CS/
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.